Journal of Viral Hepatitis

Hepatitis C virus replicons: dinosaurs still in business?
pp. 1-9(9)
Authors: Woerz, I.; Lohmann, V.; Bartenschlager, R.

Hepatitis C virus-specific T-cell immune responses in seronegative injection drug users
pp. 10-20(11)
Authors: Zeremski, M.; Shu, M. A.; Brown, Q.; Wu, Y.; Des Jarlais, D. C.; Busch, M. P.; Talal, A. H.; Edlin, B. R.

HCV RNA in peripheral blood cell subsets in HCV-HIV coinfected patients at the end of PegIFN/RBV treatment is associated with virologic relapse
pp. 21-27(7)
Authors: de Felipe, B.; Leal, M.; Soriano-Sarabia, N.; Gutiérrez, A.; López-Cortés, L.; Molina-Pinelo, S.; Vallejo, A.

Early discontinuation of ribavirin in HCV-2 and HCV-3 patients responding to Peg-interferon alpha-2a and ribavirin
pp. 28-35(8)
Authors: Andriulli, A.; Cursaro, C.; Cozzolongo, R.; Iacobellis, A.; Valvano, M. R.; Mangia, A.; Minerva, N.; Bacca, D.; Stanzione, M.; Scuteri, A.; Montalto, G.; Andreone, P.

Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B
pp. 36-44(9)
Authors: Chan, H. L.-Y.; Wong, G. L.-H.; Choi, P. C.-L.; Chan, A. W.-H.; Chim, A. M.-L.; Yiu, K. K.-L.; Chan, F. K.-L.; Sung, J. J.-Y.; Wong, V. W.-S.

A non-synonymous single nucleotide polymorphism in IFNAR1 affects susceptibility to chronic hepatitis B virus infection
pp. 45-52(8)
Authors: Zhou, J.; Smith, D. K.; Lu, L.; Poon, V. K. M.; Ng, F.; Chen, D.-Q.; Huang, J.-D.; Yuen, K.-Y.; Cao, K.-Y.; Zheng, B.-J.

How big is the financial burden of hepatitis B to society? A cost-of-illness study of hepatitis B infection in Singapore
pp. 53-63(11)
Authors: Ong, S. C.; Lim, S. G.; Li, S. C.

Genotype D amongst injection drug users with acute hepatitis B virus infection in British Columbia
pp. 64-73(10)
Authors: Panessa, C.; Hill, W. D.; Giles, E.; Yu, A.; Harvard, S.; Butt, G.; Andonov, A.; Krajden, M.; Osiowy, C.